September 2, 2002
As reported in PJ No. 1808, Chuikyo approved the NHI price of AstraZeneca's Iressa Tablet 250 (gefitinib), a drug for non-small cell lung cancer (NSCLC), at its general assembly on August 21. The drug has already been in general clinical...read more